BLRX.TA
BioLine RX Ltd
Price:  
1.9 
USD
Volume:  
1,152,364
Israel | Biotechnology

BLRX.TA WACC - Weighted Average Cost of Capital

The WACC of BioLine RX Ltd (BLRX.TA) is 10.8%.

The Cost of Equity of BioLine RX Ltd (BLRX.TA) is 9.55%.
The Cost of Debt of BioLine RX Ltd (BLRX.TA) is 18.55%.

RangeSelected
Cost of equity8.1% - 11.0%9.55%
Tax rate23.0% - 23.0%23%
Cost of debt7.0% - 30.1%18.55%
WACC7.4% - 14.2%10.8%
WACC

BLRX.TA WACC calculation

CategoryLowHigh
Long-term bond rate4.8%5.3%
Equity market risk premium5.6%6.6%
Adjusted beta0.570.78
Additional risk adjustments0.0%0.5%
Cost of equity8.1%11.0%
Tax rate23.0%23.0%
Debt/Equity ratio
0.350.35
Cost of debt7.0%30.1%
After-tax WACC7.4%14.2%
Selected WACC10.8%

BLRX.TA's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for BLRX.TA:

cost_of_equity (9.55%) = risk_free_rate (5.05%) + equity_risk_premium (6.10%) * adjusted_beta (0.57) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.